TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: lab-induced slip outcome (fall or recovery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worker retention during 12 weeks of falls tracking
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time to achieving SARS-CoV-2 clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of participants with SARS-CoV-2 clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Arts' Dumping Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of wound dressing changes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum Observed Concentration (Cmax) of Cis-Ceftibuten (CTB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of CTB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heavy drinking episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Alcohol-related negative consequences
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction of Abscesses and inflammatory nodules (AN) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical response with resolution of DFI signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eligible PCPs or their PLWD/care partners who view or click on information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Days With Weight-monitoring on Sensor Logs at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of adverse events (Low-risk stratum)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events (High-risk stratum)
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of PTS-positive Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in KCCQ clinical summary score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Complete wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of participants with Dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline current mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative incidence of BCRL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of [14C]-LY3866288 Dose Excreted in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fraction of Dose [14C]-LY3866288 Excreted in Feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Bioavailability (Fabs) of LY3866288
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Forward-Step-Down Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trail making Test Parts A and B
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Activity-specific Balance Confidence Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Parkinson's Disease Questionnaire - Short Form (8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Hiatal Hernia Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent of subjects with TTR amyloid deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reliability of the Brief Infant Sleep Questionnaire Revised (BISQ-R)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Duration of reincarceration
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participants with detectable anti-orthopox antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quantification of anti-orthopox antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first event (all-cause death, HTx, long-term LVAD implant, etc.)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Vaginal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Vaginal Interleukin-6 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Urinary microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Urinary Interleukin-6 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in skeletal muscle dystrophin protein by immunoblot (Western blot)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-CoV-2 infectious viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Cerebrovascular Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in NIH Tool Box Composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity of a Montreal Cognitive Assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Symbol Search and Digit Symbol (WAIS-III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rey-Complex Figure Test (ROCFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Forced Expiratory Volume in the 1st second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Voice Health Index (VHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consensus Auditory Perceptual Evaluation of Voice (CAPE-V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receptor-Binding Domain (RBD) antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of tibiofemoral cartilage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of Western Ontario and McMaster Universities Osteoarthritis Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Cumulative Amount of Total Radioactivity (CumAe) Excreted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Observed Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC(0-∞))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Aortic transvalvular gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peer counselor fidelity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Attendance in the first four sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completion of the 3 month assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the Yuva Sath Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax of ARS-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of ARS-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax of ARS-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: BIRC-assessed progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Pulmonary Function: FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Quality of Life: SF-36 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Neuropsychological Status: RBANS Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: acceptability of the intervention by patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: acceptability of the intervention by interdisciplinary team members
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patients' willingness to participate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ratings of subjective drug effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concentration of THC, CBD and metabolites in whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroke-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: VAPS change score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: OAB-Q SF change score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hospital Anxiety and Depression Scale change score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change baseline of micturition episodes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of Bacteria in Shoulder Culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Nitric Oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Socket Comfort Score (SCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: reduced surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Perfusion Index Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interference with Daily Living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: First stage of labor duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Quad muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to sport
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serologic responses to pneumococcal vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TB screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TB diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TPT prevention outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving ≥ 2 mm Reduction in Proptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate analgesic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of valvular heart disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delivery before 32 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: Baby death
Endpoint domain: Mortality/survival
Primary endpoint: Change in symptomatic seroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SI joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Protective Behavioral Strategies-20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Young Adult Alcohol Consequences Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Indication of Drinking and Strategy Use
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Grip strength test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence for each tumor of the patients included in the ROC platform
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence for each tumor of the patients included in the ROC platform
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of use of the services of the ROC platform
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnostic accuracy of native T1 LV mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of effective self-administrations of zilucoplan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in muscle fatigue assessment
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in isokinetic muscle force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in blood supply
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Child Mental Health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Teacher EBI practices
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Teacher Stress Management
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percent Change From Baseline in Seizure Frequency Per 28 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Seizure Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Climate Literacy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: School motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy and safety of non-sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent respiratory depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain assessment using McGill Pain Scale Short Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body temperature (°C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in the BSA involvement of GA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent change in the Cutaneous Sarcoidosis Activity and Morphology Instrument (CSAMI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency and nature of ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: metabolic changes in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and frequency of treatment emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: ASQ3® score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HDV RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality and disability after admission to Stroke unit
Endpoint domain: Mortality/survival
Primary endpoint: Change in mean seated systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QUALAS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Facial scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSQ questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of DS-MCE in detecting active bleeding and bleeding lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Probability of Engagement initiation
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Functional brain connectivity characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Somatosensory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood Pressure Regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Forced expiratory flow at 25-75% of FVC (FEF25-75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Functional and microstructural abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of change in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completeness for standard station scanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving Observed During Pleasant Compared to Neutral OC Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time of the maximum drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the drug concentration time curve from time zero to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Vigilance and Awareness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physician-Assessed Disease Severity Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of Atopic Dermatitis Control Tool (ADCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in distress score from baseline to 3 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in distress score from baseline to 12 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Pre-ablation Mapping Requirements and Clinically Indicated Mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) Within 7 Days of Index Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of edoxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reciprocal social cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reciprocal rigid patterns of behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-Year Recurrence-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS-I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular Ejection Fraction (LVEF) measured by 2D Echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Ventricular Ejection Fraction (LVEF) measured by 3D Echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of high sensitive-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: No vomiting rate within 72 hours after extubation
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of CAR-T cells in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of adverse events and dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with vIGA-AD success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of HIV self-test kits distributed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quantity of contraceptives distributed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to Cabenuva Injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to Primary Care Appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to Mental Health/Behavioral Appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence to Substance Abuse Appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maxillar growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QF muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes